Did you mean ertugliflozin pivalate and sitagliptin phosphate?
Displaying drugs 13476 - 13500 of 14390 in total
Human Recombinant Bone Morphogenetic Protein 4
Investigational
Ferritarg P
Investigational
Trastuzumab vedotin
Investigational
Immucin
Investigational
LuLym-T
LuLym-T is an investigational autologous immune cell therapy consisting of activated T Lymphocytes. Developed by Lukas Biomedical, Inc., it is currently being investigated in hepatocellular carcinoma.
Investigational
KITE-585
KITE-585 is an autologous, fully-human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy. It is being investigated in the treatment of multiple myeloma.
Investigational
BS-001
BS-001 is a recombinant oncolytic herpes simplex virus type II (OH2) therapeutic injection (Vero cell) for human use (rHSV2hGM-CSF).
Investigational
DCP-001
Investigational
BI-1206
BI-1206 is a fully human immunoglobulin G1 monoclonal antibody that targets CD32b.
Investigational
MT-0169
MT-0169 is a usion protein comprised of an enzymatically active Shiga-like toxin-I A1 subunit fused to a human single chain variable fragment with affinity for human CD38 cell surface protein.
Investigational
D-3082-L
D-3082-L is one of the components of the human papilloma virus (HPV) type 16 E6/E7 synthetic long peptide (SLP) vaccine ISA101b.
Investigational
BB-1701
BB-1701 is a humanized IgG1 kappa monoclonal antibody (anti-HER2 antibody) conjugated to eribulin developed by Bliss Biopharmaceutical.
Investigational
Neoantigen specific TCR-T cell therapy
Investigational
TEL540-548
TEL540-548 is a recombinant peptide consisting of the amino acid residues 540 to 548 of the human telomerase reverse transcriptase (hTERT).
Investigational
Exlinkibart
Investigational
Ezabenlimab
Investigational
Pegenzileukin
Investigational
NY-ESO-1 peptide vaccine
NY-ESO-1 peptide vaccine is an investigational cancer immunotherapy. It contains a peptide derived from the cancer-testis antigen (NY-ESO-1).
Investigational
TILT-123
Investigational
TRX-518
Investigational
Luveltamab tazevibulin
Luveltamab tazevibulin, formerly known as STRO-002, is novel homogeneous folate receptor alpha (FolRα) targeting antibody-drug conjugate. It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer).
Investigational
DCVax-L
DCVax-L is a personalized immunotherapy comprising an autologous vaccine with dendritic cells loaded in vitro with autologous tumour lysate.
Investigational
Strimvelis
Investigational
Displaying drugs 13476 - 13500 of 14390 in total